Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gauri G Rao

Showing results (31-40 of 78) with videos related to

Pageof 8
Sort By:
International Journal of Antimicrobial Agents|March 31, 2021
Polymyxins for the treatment of lower respiratory tract infections: lessons learned from the integration of clinical pharmacokinetic studies and clinical outcomesThamer A Almangour, Estefany Garcia, Qi Zhou, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 9, 2020
A mechanism-based pharmacokinetic model of remdesivir leveraging interspecies scaling to simulate COVID-19 treatment in humansPatrick O Hanafin, Brian Jermain, Anthony J Hickey, et al.
Pharmacotherapy|May 27, 2015
Relative bioavailability of orally administered fosphenytoin sodium injection compared with phenytoin sodium injection in healthy volunteersKevin A Kaucher, Nicole M Acquisto, Gauri G Rao, et al.
International Journal of Antimicrobial Agents|May 29, 2018
Comparison of the composition and in vitro activity of polymyxin B productsJohn K Diep, Jenna Covelli, Rajnikant Sharma, et al.
Msphere|January 9, 2023
Comparative Proteomics of Outer Membrane Vesicles from Polymyxin-Susceptible and Extremely Drug-Resistant Klebsiella pneumoniaeMaytham Hussein, Raad Jasim, Hakan Gocol, et al.
International Journal of Antimicrobial Agents|January 2, 2017
Polymyxin B in combination with meropenem against carbapenemase-producing Klebsiella pneumoniae: pharmacodynamics and morphological changesRajnikant Sharma, Saloni Patel, Cely Abboud, et al.
Computational and Structural Biotechnology Journal|November 24, 2022
Untargeted metabolomics to evaluate polymyxin B toxicodynamics following direct intracerebroventricular administration into the rat brainMaytham Hussein, Sara Oberrauch, Rafah Allobawi, et al.
Clinical Pharmacology and Therapeutics|February 6, 2021
Evaluation Strategies for Triple-Drug Combinations against Carbapenemase-Producing Klebsiella Pneumoniae in an In Vitro Hollow-Fiber Infection ModelEstefany Garcia, John K Diep, Rajnikant Sharma, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 3, 2023
Pharmacokinetics/pharmacodynamics of phage therapy: a major hurdle to clinical translationSue C Nang, Yu-Wei Lin, Aleksandra Petrovic Fabijan, et al.
Antimicrobial Agents and Chemotherapy|November 12, 2025
Hyperforin potentiates polymyxin B against multidrug-resistant Gram-negative pathogens via membrane disruption, biofilm eradication, and oxidative stressMaytham Hussein, Simon Crawford, Mark Baker, et al.
Pageof 8

Showing results (31-40 of 78) with videos related to

Sort By:
Pageof 8
International Journal of Antimicrobial Agents|March 31, 2021
Polymyxins for the treatment of lower respiratory tract infections: lessons learned from the integration of clinical pharmacokinetic studies and clinical outcomesThamer A Almangour, Estefany Garcia, Qi Zhou, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 9, 2020
A mechanism-based pharmacokinetic model of remdesivir leveraging interspecies scaling to simulate COVID-19 treatment in humansPatrick O Hanafin, Brian Jermain, Anthony J Hickey, et al.
Pharmacotherapy|May 27, 2015
Relative bioavailability of orally administered fosphenytoin sodium injection compared with phenytoin sodium injection in healthy volunteersKevin A Kaucher, Nicole M Acquisto, Gauri G Rao, et al.
International Journal of Antimicrobial Agents|May 29, 2018
Comparison of the composition and in vitro activity of polymyxin B productsJohn K Diep, Jenna Covelli, Rajnikant Sharma, et al.
Msphere|January 9, 2023
Comparative Proteomics of Outer Membrane Vesicles from Polymyxin-Susceptible and Extremely Drug-Resistant Klebsiella pneumoniaeMaytham Hussein, Raad Jasim, Hakan Gocol, et al.
International Journal of Antimicrobial Agents|January 2, 2017
Polymyxin B in combination with meropenem against carbapenemase-producing Klebsiella pneumoniae: pharmacodynamics and morphological changesRajnikant Sharma, Saloni Patel, Cely Abboud, et al.
Computational and Structural Biotechnology Journal|November 24, 2022
Untargeted metabolomics to evaluate polymyxin B toxicodynamics following direct intracerebroventricular administration into the rat brainMaytham Hussein, Sara Oberrauch, Rafah Allobawi, et al.
Clinical Pharmacology and Therapeutics|February 6, 2021
Evaluation Strategies for Triple-Drug Combinations against Carbapenemase-Producing Klebsiella Pneumoniae in an In Vitro Hollow-Fiber Infection ModelEstefany Garcia, John K Diep, Rajnikant Sharma, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 3, 2023
Pharmacokinetics/pharmacodynamics of phage therapy: a major hurdle to clinical translationSue C Nang, Yu-Wei Lin, Aleksandra Petrovic Fabijan, et al.
Antimicrobial Agents and Chemotherapy|November 12, 2025
Hyperforin potentiates polymyxin B against multidrug-resistant Gram-negative pathogens via membrane disruption, biofilm eradication, and oxidative stressMaytham Hussein, Simon Crawford, Mark Baker, et al.
Pageof 8